BioPharm News

Jun 10, 2010
BioPharm International
By BioPharm International Editors
The US Food and Drug Administration has approved Prolia (denosumab), manufactured by Amgen Inc. (Thousand Oaks, CA), for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.
Jun 10, 2010
BioPharm International
By BioPharm International Editors
A first-of-its-kind vaccine to prevent breast cancer has shown favorable results in animal models, according to a study by researchers at Cleveland Clinic?s Lerner Research Institute (Cleveland, OH).
Jun 10, 2010
BioPharm International
By BioPharm International Editors
Teva Pharmaceutical Industries (Tikva, Israel) is developing a generic version of Roche's (Basel, Switzerland) blockbuster antibody drug Rituxan, in what may possibly be the first US generic version of a monoclonal antibody.
Jun 10, 2010
BioPharm International
By BioPharm International Editors
Covidien (Dublin, Ireland), a provider of healthcare products, will sell its Specialty Chemicals business, known in the industry as two brand names, J.T.Baker and Mallinckrodt Laboratory Chemicals to an affiliate of New Mountain Capital, L.L.C. for $280 million.
Jun 10, 2010
BioPharm International
By BioPharm International Editors
The US Food and Drug Administration has cleared the Simplexa Influenza A H1N1 (2009), a test for the 2009 H1N1 influenza virus in patients with signs and symptoms of respiratory infection.
Jun 10, 2010
BioPharm International
By BioPharm International Editors
Shimadzu (Kyoto, Japan) and bioMérieux (Marcy l?Etoile, France) will commercialize a mass spectrometry system for bacterial identification in microbiology laboratories.
Jun 10, 2010
BioPharm International
By BioPharm International Editors
Abbott (Abbott Park, IL) will acquire full ownership of Piramal Healthcare Limited?s Healthcare Solutions business (Mumbai, India), a provider of Indian-branded generics, for an up front payment of $2.12 billion, plus $400 million annually for the next four years.
Jun 10, 2010
BioPharm International
In February, we reported on Pfizer's plans for reconfiguring its global manufacturing network of 79 plants, following its recent acquisition of Wyeth. Now, we have the answer.
Jun 10, 2010
BioPharm International
By BioPharm International Editors
Baxter BioScience (Deerfield, IL) and the US Food and Drug Administration have notified healthcare professionals of a market withdrawal being conducted as a precautionary measure because of an increased number of adverse event reports of allergic reactions associated with two lots of GammaGard Liquid.
Jun 09, 2010
By BioPharm International Editors
Xcellerex, Inc. has begun construction of a state-of-the-art current good manufacturing practices-compliant FlexFactory biomanufacturing facility at its headquarters in Marlborough, MA.
native1_300x100
lorem ipsum